[Treatment with rituximab for a patient with p-ANCA glomerulonephritis, alveolar bleeding and multiple relapses during haemodialysis].
M A
MA
Azancot
I
I
Agraz Pamplona
J
J
Fort Ros
A
A
Marín Valencia
I
I
Gil Carballeira
J
J
Camps Domenech
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005884:Gingival Hemorrhage / Q000209:etiology*; D005921:Glomerulonephritis / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008171:Lung Diseases / Q000209:etiology; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D006435:Renal Dialysis; D000069283:Rituximab; D056647:Systemic Vasculitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D009173:Mycophenolic Acid